Nakajima Kunihiro, Tanaka Yasushi, Nomiyama Takashi, Ogihara Takeshi, Ikeda Fuki, Kanno Rei, Iwashita Noseki, Sakai Ken, Watada Hirotaka, Onuma Tomio, Kawamori Ryuzo
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan.
Diabetes Care. 2003 Mar;26(3):892-8. doi: 10.2337/diacare.26.3.892.
To evaluate the effect of RANTES gene promoter polymorphism and RANTES receptor (CCR5 gene) promoter polymorphism on diabetic nephropathy in Japanese type 2 diabetic subjects.
A total 616 Japanese subjects with type 2 diabetes were recruited. Polymorphisms of -28 C/G and -403 G/A in the RANTES gene promoter region, and of 59029 G/A in the CCR5 gene promoter region were detected by PCR-RFLP (restriction fragment length polymorphism). The association of these genotypes with nephropathy was analyzed.
While the RANTES -403 genotype showed no association with nephropathy, the frequency of the -28G allele was significantly higher in the DN2 group (urinary albuminuria-to-creatinine ratio [ACR] >or=300 mg/g creatinine, serum creatinine <2.0 mg/dl) than in the DN0 (ACR <30 mg/g creatinine) and DN1 (ACR >or=30 mg/g creatinine and <300 mg/g creatinine) groups. The frequency of a RANTES -28G-positive genotype (C/G or G/G) was higher in the DN2 group than in the DN0 and DN1 groups (34% vs. 25 and 20%, P = 0.0268, chi(2) = 4.905), and the frequency of a CCR5 59029 A-positive genotype (G/A or A/A) was higher in the DN1 and DN2 groups than in the DN0 group (84 and 85% vs. 76%, P = 0.0123, chi(2) = 6.269). Discriminant analysis showed that the RANTES -28G-positive genotype and CCR5 59029A-positive genotype were independently associated with nephropathy. The percentage of macroalbuminuria was twofold higher in the subjects having -28G or 59029A and threefold higher in the subjects having -28G and 59029A than in the subjects without -28G and 59029A.
The RANTES promoter -28G genotype and CCR5 promoter 59029A genotype may be independent risk factors for diabetic nephropathy in patients with type 2 diabetes and may have an additive effect on nephropathy.
评估调节激活正常T细胞表达和分泌因子(RANTES)基因启动子多态性及RANTES受体(CCR5基因)启动子多态性对日本2型糖尿病患者糖尿病肾病的影响。
共招募616名日本2型糖尿病患者。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)检测RANTES基因启动子区域-28 C/G和-403 G/A多态性以及CCR5基因启动子区域59029 G/A多态性。分析这些基因型与肾病的相关性。
虽然RANTES -403基因型与肾病无相关性,但在糖尿病肾病2期组(尿白蛋白肌酐比[ACR]≥300 mg/g肌酐,血清肌酐<2.0 mg/dl)中,-28G等位基因频率显著高于糖尿病肾病0期(ACR<30 mg/g肌酐)和糖尿病肾病1期(ACR≥30 mg/g肌酐且<300 mg/g肌酐)组。糖尿病肾病2期组中RANTES -28G阳性基因型(C/G或G/G)频率高于糖尿病肾病0期和1期组(34%对25%和20%,P = 0.0268,χ² = 4.905),糖尿病肾病1期和2期组中CCR5 59029 A阳性基因型(G/A或A/A)频率高于糖尿病肾病0期组(84%和85%对76%,P = 0.0123,χ² = 6.269)。判别分析显示,RANTES -28G阳性基因型和CCR5 59029A阳性基因型与肾病独立相关。携带-28G或59029A的受试者中大量蛋白尿的百分比是未携带-28G和59029A受试者的两倍,同时携带-28G和59与029A的受试者中大量蛋白尿的百分比是未携带-28G和59029A受试者的三倍。
RANTES启动子-28G基因型和CCR5启动子59029A基因型可能是2型糖尿病患者糖尿病肾病的独立危险因素,且可能对肾病有累加效应。